Faeth Therapeutics Leadership Change
Faeth Therapeutics increased its board size from six to seven and appointed Adam Schayowitz, Ph.D., as a Class III director. Dr. Schayowitz, currently EVP and Head of R&D at Zymeworks, brings extensive oncology drug development experience from previous roles at Pfizer and Tesaro. He will receive a standard non-employee director compensation package, including an initial option to purchase 25,000 shares of common stock.